Global Hepatitis Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
Published On: October 2018
 
Report ID:301293
 
 
Pages: 131




Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.

Scope of the Report:

This report focuses on the Hepatitis Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Factors such as growth in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.

The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2017. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.

The worldwide market for Hepatitis Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

F. Hoffmann-La Roche

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Vertex Pharmaceuticals

Abbvie

Achillion Pharmaceuticals

Bristol-Myers Squibb

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

VEMLIDY

EPCLUSA

SOVALDI

INCIVEK

OLYSIO

VICTRELIS

VIREAD

HEPSERA

BARACLUDE

TYZEKA

Market Segment by Applications, can be divided into

Hepatitis A

Hepatitis B

Hepatitis C

Hepatitis D

Hepatitis E

There are 15 Chapters to deeply display the global Hepatitis Drugs market.

Chapter 1, to describe Hepatitis Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Hepatitis Drugs, with sales, revenue, and price of Hepatitis Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Hepatitis Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Hepatitis Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Hepatitis Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Table of Contents

1 Market Overview

1.1 Hepatitis Drugs Introduction

1.2 Market Analysis by Type

1.2.1 VEMLIDY

1.2.2 EPCLUSA

1.2.3 SOVALDI

1.2.4 INCIVEK

1.2.5 OLYSIO

1.2.6 VICTRELIS

1.2.7 VIREAD

1.2.8 HEPSERA

1.2.9 BARACLUDE

1.2.10 TYZEKA

1.3 Market Analysis by Applications

1.3.1 Hepatitis A

1.3.2 Hepatitis B

1.3.3 Hepatitis C

1.3.4 Hepatitis D

1.3.5 Hepatitis E

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 F. Hoffmann-La Roche

2.1.1 Business Overview

2.1.2 Hepatitis Drugs Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 F. Hoffmann-La Roche Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Gilead Sciences

2.2.1 Business Overview

2.2.2 Hepatitis Drugs Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Gilead Sciences Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 GlaxoSmithKline

2.3.1 Business Overview

2.3.2 Hepatitis Drugs Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 GlaxoSmithKline Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Johnson & Johnson

2.4.1 Business Overview

2.4.2 Hepatitis Drugs Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Johnson & Johnson Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Merck

2.5.1 Business Overview

2.5.2 Hepatitis Drugs Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Merck Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Novartis

2.6.1 Business Overview

2.6.2 Hepatitis Drugs Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Novartis Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Vertex Pharmaceuticals

2.7.1 Business Overview

2.7.2 Hepatitis Drugs Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Vertex Pharmaceuticals Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Abbvie

2.8.1 Business Overview

2.8.2 Hepatitis Drugs Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Abbvie Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9 Achillion Pharmaceuticals

2.9.1 Business Overview

2.9.2 Hepatitis Drugs Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Achillion Pharmaceuticals Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10 Bristol-Myers Squibb

2.10.1 Business Overview

2.10.2 Hepatitis Drugs Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Bristol-Myers Squibb Hepatitis Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Hepatitis Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Hepatitis Drugs Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Hepatitis Drugs Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Hepatitis Drugs Manufacturer Market Share in 2017

3.3.2 Top 6 Hepatitis Drugs Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Hepatitis Drugs Market Analysis by Regions

4.1 Global Hepatitis Drugs Sales, Revenue and Market Share by Regions

4.1.1 Global Hepatitis Drugs Sales and Market Share by Regions (2013-2018)

4.1.2 Global Hepatitis Drugs Revenue and Market Share by Regions (2013-2018)

4.2 North America Hepatitis Drugs Sales and Growth Rate (2013-2018)

4.3 Europe Hepatitis Drugs Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Hepatitis Drugs Sales and Growth Rate (2013-2018)

4.5 South America Hepatitis Drugs Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Hepatitis Drugs Sales and Growth Rate (2013-2018)

5 North America Hepatitis Drugs by Countries

5.1 North America Hepatitis Drugs Sales, Revenue and Market Share by Countries

5.1.1 North America Hepatitis Drugs Sales and Market Share by Countries (2013-2018)

5.1.2 North America Hepatitis Drugs Revenue and Market Share by Countries (2013-2018)

5.2 United States Hepatitis Drugs Sales and Growth Rate (2013-2018)

5.3 Canada Hepatitis Drugs Sales and Growth Rate (2013-2018)

5.4 Mexico Hepatitis Drugs Sales and Growth Rate (2013-2018)

6 Europe Hepatitis Drugs by Countries

6.1 Europe Hepatitis Drugs Sales, Revenue and Market Share by Countries

6.1.1 Europe Hepatitis Drugs Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Hepatitis Drugs Revenue and Market Share by Countries (2013-2018)

6.2 Germany Hepatitis Drugs Sales and Growth Rate (2013-2018)

6.3 UK Hepatitis Drugs Sales and Growth Rate (2013-2018)

6.4 France Hepatitis Drugs Sales and Growth Rate (2013-2018)

6.5 Russia Hepatitis Drugs Sales and Growth Rate (2013-2018)

6.6 Italy Hepatitis Drugs Sales and Growth Rate (2013-2018)

7 Asia-Pacific Hepatitis Drugs by Countries

7.1 Asia-Pacific Hepatitis Drugs Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Hepatitis Drugs Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Hepatitis Drugs Revenue and Market Share by Countries (2013-2018)

7.2 China Hepatitis Drugs Sales and Growth Rate (2013-2018)

7.3 Japan Hepatitis Drugs Sales and Growth Rate (2013-2018)

7.4 Korea Hepatitis Drugs Sales and Growth Rate (2013-2018)

7.5 India Hepatitis Drugs Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Hepatitis Drugs Sales and Growth Rate (2013-2018)

8 South America Hepatitis Drugs by Countries

8.1 South America Hepatitis Drugs Sales, Revenue and Market Share by Countries

8.1.1 South America Hepatitis Drugs Sales and Market Share by Countries (2013-2018)

8.1.2 South America Hepatitis Drugs Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Hepatitis Drugs Sales and Growth Rate (2013-2018)

8.3 Argentina Hepatitis Drugs Sales and Growth Rate (2013-2018)

8.4 Colombia Hepatitis Drugs Sales and Growth Rate (2013-2018)

9 Middle East and Africa Hepatitis Drugs by Countries

9.1 Middle East and Africa Hepatitis Drugs Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Hepatitis Drugs Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Hepatitis Drugs Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Hepatitis Drugs Sales and Growth Rate (2013-2018)

9.3 UAE Hepatitis Drugs Sales and Growth Rate (2013-2018)

9.4 Egypt Hepatitis Drugs Sales and Growth Rate (2013-2018)

9.5 Nigeria Hepatitis Drugs Sales and Growth Rate (2013-2018)

9.6 South Africa Hepatitis Drugs Sales and Growth Rate (2013-2018)

10 Global Hepatitis Drugs Market Segment by Type

10.1 Global Hepatitis Drugs Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Hepatitis Drugs Sales and Market Share by Type (2013-2018)

10.1.2 Global Hepatitis Drugs Revenue and Market Share by Type (2013-2018)

10.2 VEMLIDY Sales Growth and Price

10.2.1 Global VEMLIDY Sales Growth (2013-2018)

10.2.2 Global VEMLIDY Price (2013-2018)

10.3 EPCLUSA Sales Growth and Price

10.3.1 Global EPCLUSA Sales Growth (2013-2018)

10.3.2 Global EPCLUSA Price (2013-2018)

10.4 SOVALDI Sales Growth and Price

10.4.1 Global SOVALDI Sales Growth (2013-2018)

10.4.2 Global SOVALDI Price (2013-2018)

10.5 INCIVEK Sales Growth and Price

10.5.1 Global INCIVEK Sales Growth (2013-2018)

10.5.2 Global INCIVEK Price (2013-2018)

10.6 OLYSIO Sales Growth and Price

10.6.1 Global OLYSIO Sales Growth (2013-2018)

10.6.2 Global OLYSIO Price (2013-2018)

10.7 VICTRELIS Sales Growth and Price

10.7.1 Global VICTRELIS Sales Growth (2013-2018)

10.7.2 Global VICTRELIS Price (2013-2018)

10.8 VIREAD Sales Growth and Price

10.8.1 Global VIREAD Sales Growth (2013-2018)

10.8.2 Global VIREAD Price (2013-2018)

10.9 HEPSERA Sales Growth and Price

10.9.1 Global HEPSERA Sales Growth (2013-2018)

10.9.2 Global HEPSERA Price (2013-2018)

10.10 BARACLUDE Sales Growth and Price

10.10.1 Global BARACLUDE Sales Growth (2013-2018)

10.10.2 Global BARACLUDE Price (2013-2018)

10.11 TYZEKA Sales Growth and Price

10.11.1 Global TYZEKA Sales Growth (2013-2018)

10.11.2 Global TYZEKA Price (2013-2018)

11 Global Hepatitis Drugs Market Segment by Application

11.1 Global Hepatitis Drugs Sales Market Share by Application (2013-2018)

11.2 Hepatitis A Sales Growth (2013-2018)

11.3 Hepatitis B Sales Growth (2013-2018)

11.4 Hepatitis C Sales Growth (2013-2018)

11.5 Hepatitis D Sales Growth (2013-2018)

11.6 Hepatitis E Sales Growth (2013-2018)

12 Hepatitis Drugs Market Forecast (2018-2023)

12.1 Global Hepatitis Drugs Sales, Revenue and Growth Rate (2018-2023)

12.2 Hepatitis Drugs Market Forecast by Regions (2018-2023)

12.2.1 North America Hepatitis Drugs Market Forecast (2018-2023)

12.2.2 Europe Hepatitis Drugs Market Forecast (2018-2023)

12.2.3 Asia-Pacific Hepatitis Drugs Market Forecast (2018-2023)

12.2.4 South America Hepatitis Drugs Market Forecast (2018-2023)

12.2.5 Middle East and Africa Hepatitis Drugs Market Forecast (2018-2023)

12.3 Hepatitis Drugs Market Forecast by Type (2018-2023)

12.3.1 Global Hepatitis Drugs Sales Forecast by Type (2018-2023)

12.3.2 Global Hepatitis Drugs Market Share Forecast by Type (2018-2023)

12.4 Hepatitis Drugs Market Forecast by Application (2018-2023)

12.4.1 Global Hepatitis Drugs Sales Forecast by Application (2018-2023)

12.4.2 Global Hepatitis Drugs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source




Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \


Copyright © 2020 Fior Market Research LLP, All Rights Reserved.